El Helali A, Plummer R, Jayson GC, Coyle VM, et al. A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours. Br J Cancer 2022 May 14. pii: 10.1038/s41416-022-01780.
PMID: 35568736